Qingdao Vland Biotech Co Ltd
Qingdao Vland Biotech INC. engages in the research and development, production, and sale of enzyme preparations, microecological preparations, and animal health products in China and internationally. It offers feed, industrial, and food enzymes; and probiotics, including aquaculture premixes, health products, and animal and plant probiotics. The company also offers animal vaccines and biological … Read more
Qingdao Vland Biotech Co Ltd - Asset Resilience Ratio
Qingdao Vland Biotech Co Ltd (603739) has an Asset Resilience Ratio of 7.33% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Qingdao Vland Biotech Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Qingdao Vland Biotech Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥223.10 Million | 7.33% |
| Total Liquid Assets | CN¥223.10 Million | 7.33% |
Asset Resilience Insights
- Limited Liquidity: Qingdao Vland Biotech Co Ltd maintains only 7.33% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Qingdao Vland Biotech Co Ltd Industry Peers by Asset Resilience Ratio
Compare Qingdao Vland Biotech Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Qingdao Vland Biotech Co Ltd (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Qingdao Vland Biotech Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 6.69% | CN¥199.34 Million | CN¥2.98 Billion | -2.94pp |
| 2023-12-31 | 9.63% | CN¥292.05 Million | CN¥3.03 Billion | +1.40pp |
| 2022-12-31 | 8.22% | CN¥212.02 Million | CN¥2.58 Billion | +0.55pp |
| 2021-12-31 | 7.67% | CN¥170.43 Million | CN¥2.22 Billion | +0.96pp |
| 2020-12-31 | 6.71% | CN¥97.45 Million | CN¥1.45 Billion | -7.56pp |
| 2019-12-31 | 14.28% | CN¥182.90 Million | CN¥1.28 Billion | -- |